Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: Second-line pemetrexed followed by third-line erlotinib versus the reverse sequence

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3397-3402

  Fiala, Ondrej ^a   Pesek, Milos ^a   Finek, Jindrich ^a   Benesova, Lucie ^b   Bortlicek, Zbynek ^c   Minarik, Marek ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Genomac Research Institute   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Adenocarcinoma; Erlotinib; NSCLC; Pemetrexed; Second line; Sequence; Third line

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CLINICAL ASSESSMENT; DNA SEQUENCE; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SMOKING; THORAX RADIOGRAPHY;

ADENOCARCINOMA; ERLOTINIB; NSCLC; PEMETREXED; SECOND-LINE; SEQUENCE; THIRD-LINE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84883306378     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Wahbah M, Boroumand N, Castro C, El-Zeky F and Eltorky M: Changing trends in the distribution of the histologic types of lung cancer: A review of 4,439 cases. Ann Diagn Pathol 11: 89-96, 2007.
3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
4. Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martínez-Barrera L, Barraclough H, van Kooten M and Orlando M: A randomized phase III trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 6: 1907-14, 2011.
5. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L and National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small cell lung cancer. J Clin Oncol 23: 2544-2555, 2005.
7. Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M and Heigener D: Erlotinib in advanced nonsmall cell lung cancer: Efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 10: 1616-1622, 2010.
8. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L and You C: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase III study. Lancet Oncol 12: 735-742, 2011.
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): A multicentre, open-label, randomised phase III trial. Lancet Oncol 13: 239-246, 2012.
10. Stenner F, Chastonay R, Liewen H, Haile SR, Cathomas R, Rothermundt C, Siciliano RD, Stoll S, Knuth A, Buchler T, Porta C, Renner C and Samaras P: A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology 82: 333-340, 2012.
11. Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V and Bajetta E: Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma (RCC): An Italian multicentre retrospective analysis of 189 patient cases. BJU Int 108(8 Pt 2): E250-257, 2011.
12. Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J and Escudier B: Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182: 29-34, 2009.
13. Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H and Heinzer H: Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: A retrospective outcome analysis. Eur Urol 54: 1373-1378, 2008.
14. Ambring A, Björholt I, Lesén E, Stierner U and Odén A: Treatment with sorafenib and sunitinib in renal cell cancer: A Swedish register-based study. Med Oncol 30: 331, 2013.
15. Hong T, Zhang R, Cai D, Wu X and Hua D: Second-line epidermal growth factor receptor inhibitors followed by thirdline pemetrexed or the reverse sequence: A retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol 138: 285-291, 2012.
16. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
17. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
18. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S and Halmos B: EGFR-mutated lung cancer: A paradigm of molecular oncology. Oncotarget 1: 497-514, 2010.
19. Sequist LV, Bell DW, Lynch TJ and Haber DA: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small cell lung cancer. J Clin Oncol 25: 587-595, 2007.
20. Gandara DR, Lara PN Jr., Mack P and Scagliotti G: Individualizing therapy for non-small cell lung cancer: A paradigm shift from empiric to integrated decision-making. Clin Lung Cancer 10: 148-150, 2009.
21. West H, Lilenbaum R, Harpole D, Wozniak A and Sequist L: Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol 4(9 Suppl 2): S1029-1039, 2009.
22. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G and Peters GJ: Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in nonsmall cell lung cancer cells. Mol Pharmacol 73: 1290-1300, 2008.
23. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M and Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells. Mol Pharmacol 68: 110-118, 2005.
24. Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X, Bauer NL, Hockett RD, Chen VJ, Niyikiza C and Hanauske AR: A phase II trial of pemetrexed in advanced breast cancer: Clinical response and association with molecular target expression. Clin Cancer Res 12(3 Pt 1): 832-838, 2006.
25. She QB, Solit D, Basso A and Moasser MM: Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/AKT pathway signaling. Clin Cancer Res 9: 4340-4346, 2003.
26. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB and Arteaga CL: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812-2822, 2003.
27. Janmaat ML, Kruyt FA, Rodriguez JA and Giaccone G: Response to epidermal growth factor receptor inhibitors in nonsmall cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or AKT kinase pathways. Clin Cancer Res 9: 2316-2326, 2003.